

# DARWIN EU® Prevalence of rare blood cancers in Europe

**First published:** 31/01/2023

**Last updated:** 12/06/2024

Study

Finalised

## Administrative details

### PURI

<https://redirect.ema.europa.eu/resource/50801>

### EU PAS number

EUPAS50800

### Study ID

50801

### DARWIN EU® study

Yes

### Study countries

Belgium

Germany

Netherlands

Spain

United Kingdom

### Study description

In this study the prevalence of rare blood cancers (follicular lymphoma, diffuse large B-Cell lymphoma, multiple myeloma, chronic lymphocytic leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia) will be assessed.

### Study status

Finalised

## Research institution and networks

## Institutions

### Department of Medical Informatics - Health Data Science, Erasmus Medical Center (ErasmusMC)

Netherlands

**First published:** 03/11/2022

Last updated

02/05/2024

Institution

Educational Institution

ENCePP partner

### Real-World-Evidence, IQVIA NL

Netherlands

**First published:** 25/11/2022

Last updated

20/06/2024

Institution

Other

ENCePP partner

### Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

Spain

**First published:** 05/10/2012

Last updated

23/02/2024

Institution

Educational Institution

Laboratory/Research/Testing facility

Not-for-profit

ENCePP partner

### University of Oxford

## Networks

# Data Analysis and Real World Interrogation Network (DARWIN EU®)

Belgium

Croatia

Denmark

Estonia

Finland

France

Germany

Hungary

Netherlands

Norway

Portugal

Spain

United Kingdom

**First published:** 01/02/2024

Last updated 11/06/2024

Network

## Contact details

### Study institution contact

Edward Burn

Study contact

[e.burn@darwin-eu.org](mailto:e.burn@darwin-eu.org)

### Primary lead investigator

Edward Burn

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned:

13/05/2022

Actual:

13/05/2022

---

### Study start date

Planned:  
01/11/2022  
Actual:  
01/11/2022

---

#### **Date of final study report**

Planned:  
28/03/2023  
Actual:  
28/03/2023

## Sources of funding

- EMA

## Study protocol

[D2.2.3\\_DARWIN\\_EU\\_Study Protocol C1-001\\_v2.0\\_EU\\_PAS.pdf](#)(1.04 MB)

## Regulatory

**Was the study required by a regulatory body?**

Yes

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

---

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Disease /health condition

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

**Data collection methods:**

Secondary data collection

---

**Main study objective:**

To estimate the prevalence of rare blood cancers (follicular lymphoma, diffuse Large B-Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic Leukaemia)

## Study Design

**Non-interventional study design**

Cohort

Other

---

**Non-interventional study design, other**

Population-based

## Study drug and medical condition

**Medical condition to be studied**

Follicular lymphoma

Diffuse large B-cell lymphoma

Plasma cell myeloma

Chronic lymphocytic leukaemia

Acute myeloid leukaemia

Acute lymphocytic leukaemia

## Population studied

**Short description of the study population**

The study included all individuals reported in the five European databases, including IPCI, SIDIAP, CPRD, IQVIA LPD Belgium, and IQVIA DA Germany, to determine the prevalence of haematological cancers.

---

## Age groups

Preterm newborn infants (0 – 27 days)

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

## Special population of interest

Other

---

## Special population of interest, other

Patients with haematological cancers

---

## Estimated number of subjects

10000000

# Study design details

## Outcomes

Follicular lymphoma, diffuse Large B-Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic.

---

## Data analysis plan

5-year partial prevalence will be estimated for each outcome of interest.

# Documents

## Study results

[DARWIN\\_EU\\_Study\\_Report\\_C1-001\\_V3.2.pdf](#)(1.49 MB)

---

# Data management

# Data sources

**Data source(s)**

IPCI

The Information System for Research in Primary Care (SIDIAP)

Clinical Practice Research Datalink

Longitudinal Patient Data - Belgium

---

**Data sources (types)**

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

**CDM mapping**

Yes

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No